Feb 6 (Reuters) - AstraZeneca ( AZN ) forecast its 2025
sales above analysts' expectations on Thursday, after the
drugmaker's fourth-quarter revenue beat estimates, driven by
robust demand, especially for its medicines for cancer and heart
diseases.